Navigation Links
Cynosure Introduces Affirm CO2(TM) Workstation for Advanced Ablative Therapy
Date:7/17/2008

- Ablative Solution to Treat Deep Wrinkles and Significant Photo Damage - Integrated Micro Ablative Scanning Technology Optimizes Patient Treatment - Newest Addition Broadens Affirm(TM) Family to Provide Industry's Most

Comprehensive Anti-Aging Solution

WESTFORD, Mass., July 17 /PRNewswire-FirstCall/ -- Cynosure, Inc. (Nasdaq: CYNO), a leading developer and manufacturer of a broad array of light-based aesthetic treatment systems, today launched the Affirm CO2(TM), an ablative workstation with a proprietary scanning delivery system that combines ablative CO2 skin resurfacing and rejuvenation in a single laser system.

"Affirm CO2 is a dynamic platform to address deep wrinkles, significant photoaging, severe scar damage and other difficult-to-treat skin conditions," said Cynosure President and Chief Executive Officer Michael Davin. "Our newest flagship workstation integrates a carbon dioxide laser, with Micro Ablative scanning technology and is considered the most effective treatment option for deep wrinkles. The result is a system that helps patients look years younger with minimal downtime, and affords physicians substantial flexibility in treatment options. The Affirm CO2 system offers a range of settings that enable physicians to customize the treatment based on the aesthetic goals and downtime expectations of individual patients."

The Affirm CO2 system with Micro Ablative scanning technology is the newest flagship addition to Cynosure's Affirm(TM) family of products for anti-aging indications. The original Affirm Workstation, introduced in 2006, delivers a non-ablative treatment designed to produce progressive results in patients with fine to moderate wrinkles and sun-damaged skin. By contrast, the Affirm CO2 workstation uses an ablative approach to target the epidermal and dermal layer with the objective of treating dyschromia, deep wrinkles and significant photoaging.

According to the Millennium Research Group, the skin rejuvenation market is expected to grow annually by 18 percent, resulting in a $239 million industry by 2010, with approximately 4.4 million procedures performed per year by 2010.

"The Affirm CO2 targets a large and growing market of consumers for whom age is not an impediment to vitality or a youthful appearance," Davin said. "In a country where 12,000 people turn 50 every day, and the population over the age of 55 is expected to grow 60% over the next 20 years, we believe the market opportunity for Cynosure is significant."

"With power up to 30 watts and an adjustable pulse duration between 0.2 and 2 milli seconds, Affirm CO2 offers the versatility of performing a light to aggressive treatment with a single laser," said Bruce Katz, M.D., Clinical Professor of Dermatology at The Mount Sinai School of Medicine, Director of the Cosmetic Surgery & Laser Clinic at Mount Sinai Medical Center and Director of the Juva Skin & Laser Center in New York. "Another important benefit is the range of scanning options, which enable users not only to shorten treatment time, but to provide uniform coverage across the entire treatment area."

Initial U.S. shipments of Affirm CO2 are expected to begin in the third quarter of 2008.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that are used by physicians and other practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular lesions, rejuvenate skin through the treatment of shallow vascular and pigmented lesions, laser lipolysis and temporarily reduce the appearance of cellulite. Cynosure's products include a broad range of laser and other light-based energy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, as well as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, or visit http://www.cynosure.com.

Forward-Looking Statements

Any statements in this press release about future expectations, plans and prospects for Cynosure, Inc., including statements about the company's expectations regarding the performance and market acceptance of the Affirm CO2 and future financial performance, as well as other statements containing the words "believes," "anticipates," "plans," "expects," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including market acceptance of the Affirm CO2, Cynosure's reliance on sole source suppliers, the inability to accurately predict the timing or outcome of regulatory decisions, changes in consumer preferences, competition in the aesthetic laser industry, economic, market, technological and other factors discussed in Cynosure's most recent Annual Report on Form 10-K and Form 10-Q each of which is filed with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.

Contact:

Scott Solomon

Vice President

Sharon Merrill Associates, Inc.

617-542-5300

ssolomon@investorrelations.com


'/>"/>
SOURCE Cynosure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cynosure Announces Schedule of Upcoming Investor Conferences
2. Cynosure Appoints H. Travis Lee as Vice President of Global Marketing
3. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
4. Cynosure Introduces Smartlipo MPX(TM) Dual Wavelength Workstation for LaserBodySculpting(SM)
5. Cynosure Announces Upcoming Investor Presentations at Cowen and Citi Investor Conferences
6. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
7. Cynosure to Announce Fourth-Quarter and Full Year 2007 Financial Results on February 12
8. Cynosure to Present at the Leerink Swann & Company/MEDACorp Aesthetics Roundtable Conference
9. Nikon Instruments Introduces New Microscopes and Illumination Stand for Education and OEM Markets
10. Liko Introduces Two Additions to Its Stat Family of Low Friction Sheets
11. Roche Introduces Program to Facilitate Corporate Pandemic Stockpiling of Tamiflu(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... 2016 , ... Aditya Humad, Acting CFO of AxioMed and Managing Partner of ... States, Axiomed is now gaining interest from Silicon Valley. “It was satisfying to complete ... on to say that, “We expect interest to continue to rise as AxioMed completes ...
(Date:12/9/2016)... , Dec. 9, 2016 /PRNewswire/ - Portage Biotech Inc. ... PBT.U), is pleased to announce that Biohaven has issued ... New Haven, Connecticut (PRWEB) Dec 9, 2016 ... "Biohaven") announced today that the U.S. Food and Drug ... request covering its drug candidate BHV-0223, an orally dissolving ...
(Date:12/8/2016)... ... December 08, 2016 , ... Lajollacooks4u, San Diego’s premier team building events ... building events, new program offerings and company expansion. , This is largely ... include groups of over 30 people. Ever since, Lajollacooks4u has seen significant demand for ...
(Date:12/8/2016)... , Dec. 8, 2016  Biotheranostics today ... the role of the Breast Cancer Index (BCI) ... breast cancer are most at-risk for disease recurrence ... include results from three studies advancing the understanding ... related to tumor biology and inform decisions related ...
Breaking Biology Technology:
(Date:12/8/2016)... 8, 2016  Singulex, Inc., the leader in Next ... into a license and supply agreement with Thermo Fisher ... provides Singulex access to Thermo Scientific BRAHMS PCT (Procalcitonin), ... is used to diagnose systemic bacterial infection and sepsis ... to aid in assessing the risk of critically ill ...
(Date:12/7/2016)... Dec. 7, 2016   Avanade is helping ... One teams in history, exploit biometric data in order ... and maintain the competitive edge against their rivals after ... Avanade has worked with Williams during the ... biometric data (heart rate, breathing rate, temperature and peak ...
(Date:12/6/2016)... Valencell , the leading innovator in ... a third consecutive year of triple digit growth for ... with a 360 percent increase in companies who have ... driven by sales of its wrist and ear Benchmark™ ... technology for hearables for fitness and healthcare applications. ...
Breaking Biology News(10 mins):